Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

BACKGROUND: Sunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict response. This analysis explored biomarkers associated with sunitinib activity and clinical benefit in patients with pNET and carcinoid tumours in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Cancer
Main Authors: Zurita, A J, Khajavi, M, Wu, H-K, Tye, L, Huang, X, Kulke, M H, Lenz, H-J, Meropol, N J, Carley, W, DePrimo, S E, Lin, E, Wang, X, Harmon, C S, Heymach, J V
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2015
Teme:
Translational Therapeutics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4385961/
https://ncbi.nlm.nih.gov/pubmed/25756398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.73
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki